OS-01: Side Effects & Safety
Part of the OS-01 Complete Guide
Partner
Shop Peptides at BioLongevity LabsResearch Peptides
BioLongevity Labs15% Off
Advertiser link — we may earn a commission at no extra cost to you.
Overall Safety Profile
As a topical cosmetic product, OS-01 has a favorable safety profile limited by the low systemic exposure of topical application. It is regulated as a cosmetic, not a pharmaceutical, and has not undergone FDA drug approval processes.
Reported Side Effects
- Mild skin irritation: Possible with any new topical product, particularly for sensitive skin
- No systemic effects reported: Topical application limits systemic exposure
Important Limitations
Independent replication of OneSkin's published results by outside research groups is limited. Long-term effects of chronic senescent cell depletion in skin are unknown. The proprietary nature of the peptide and formulation limits independent verification. The cosmetic (not drug) regulatory pathway has lower evidence requirements than pharmaceutical approval.
Potential Contraindications
- Known skin sensitivity or allergy to product ingredients
- Active skin infections or open wounds at application site
- Concurrent use of prescription retinoids (potential irritation)